Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Pharmasset
December 16, 2016
Hep C settlement pays Merck’s Idenix bill
September 22, 2016
Bubble stocks top the takeover premium charts
September 07, 2016
How Gilead could go back to basics
September 14, 2015
Therapeutic focus – new combos and genotypes the future in hep C
June 30, 2015
Celgene goes for broke
November 27, 2014
Bristol-Myers misses out again in hep C
October 23, 2014
Data in 14 has Regulus joining ranks of hep C high flyers
September 30, 2014
J&J hangs in hep C game with $1.8bn Alios takeout
July 23, 2014
Sovaldi not the first to break the bank
June 09, 2014
Biotech bull market charges with Merck’s Idenix takeout
April 09, 2014
EASL – Cost tops the agenda as hepatitis C enters post-interferon world
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 20, 2020
Vantage Pharma, Biotech & Medtech 2019 in Review
December 17, 2019
Vantage 2020 Preview
Editor's Picks
January 28, 2020
The cost to Astrazeneca of building Brilinta
January 27, 2020
Rare diseases top another strong year for novel drug approvals
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
January 16, 2020
A quiet six months for device approvals
January 22, 2020
Sanofi's geriatric pipeline fails to freshen up
